2024
Early thrombus formation is required of eccentric and heterogenous neointimal hyperplasia under disturbed flow
Bai H, Li Z, Zhang W, Thaxton C, Ohashi Y, Gonzalez L, Kano M, Yatsula B, Hwa J, Dardik A. Early thrombus formation is required of eccentric and heterogenous neointimal hyperplasia under disturbed flow. Journal Of Thrombosis And Haemostasis 2024 PMID: 39173878, DOI: 10.1016/j.jtha.2024.07.028.Peer-Reviewed Original ResearchEndothelial cell lossArteriovenous fistulaSmooth muscle cellsNeointimal hyperplasiaHeterogeneous neointimaCell lossThrombus formationMT/mG reporter miceHuman arteriovenous fistulaeInhibit neointimal hyperplasiaEarly thrombus formationAntiplatelet therapyC57BL/6 miceReporter miceAVF failureWistar ratsVenous systemJuxta-anastomotic areaMuscle cellsAnimal modelsVenous outflowEarly thrombusEndothelial cellsArterial inflowThrombus
2019
Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
Jain K, Tyagi T, Patell K, Xie Y, Kadado AJ, Lee SH, Yarovinsky T, Du J, Hwang J, Martin KA, Testani J, Ionescu CN, Hwa J. Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. EBioMedicine 2019, 44: 28-40. PMID: 31130473, PMCID: PMC6604369, DOI: 10.1016/j.ebiom.2019.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAge FactorsAgedAged, 80 and overAgingAnimalsAntioxidantsApoptosisBiomarkersBlood PlateletsCardiovascular DiseasesComorbidityDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMiddle AgedOxidation-ReductionOxidative StressPlatelet ActivationPlatelet AdhesivenessReactive Oxygen SpeciesRisk AssessmentRisk FactorsConceptsRisk patientsMouse studiesPlatelet phenotypeMajor adverse cardiovascular eventsHigh cardiovascular risk patientsAdaptive increaseAdverse cardiovascular eventsCentral pathophysiological roleCVD risk patientsCardiovascular risk patientsAggressive antiplatelet therapyEffect of comorbidityAge group 40Young healthy subjectsAntiplatelet therapyCardiovascular eventsYear age cohortAdvanced ageCVD patientsGroup 40Healthy subjectsPathophysiological roleElderly populationCardiovascular pathologyPatients